9 Distinct Types of Hair Loss That Occur in Menopause and Why Each One Requires a Different Response
Hair loss was the menopause symptom that hit hardest emotionally — harder than the hot flushes, harder than the sleep problems. There's something about watching your ponytail shrink that feels deeply personal in a way that's difficult to explain. What helped most wasn't a product — it was finally understanding which type was actually happening, because that changed everything about what to do next.
Learn more about Rose →Female Pattern Hair Loss (Androgenetic Alopecia)
This is the most common type in menopausal women and is driven by a shift in the oestrogen-to-androgen ratio as oestrogen declines, leaving androgens like dihydrotestosterone (DHT) proportionally more active at the hair follicle. The result is a gradual miniaturisation of follicles, producing progressively finer, shorter hairs — typically visible as a widening part or diffuse thinning across the crown, not a receding hairline as seen in men. Minoxidil (topical) has the strongest evidence base for this specific type, and some studies show HRT can slow or partially reverse follicle miniaturisation by restoring the hormonal balance.
Telogen Effluvium
Telogen effluvium is a reactive, diffuse shedding that occurs when a physiological or psychological stressor — including the hormonal upheaval of perimenopause itself — pushes a large number of follicles simultaneously into the resting (telogen) phase, followed by mass shedding roughly two to four months later. Unlike female pattern hair loss, it tends to be sudden, uniform across the whole scalp, and often reversible once the triggering stressor is resolved or stabilised. Thyroid dysfunction, significant weight loss, surgery, and severe emotional stress are common co-triggers in menopausal women and should be ruled out before attributing shedding solely to oestrogen decline.
Chronic Telogen Effluvium
When the shedding of telogen effluvium persists beyond six months without a clear resolving trigger, it is reclassified as chronic telogen effluvium — a poorly understood but distinct condition that disproportionately affects women between 30 and 60. The hormonal fluctuations of perimenopause appear to act as a sustained, low-grade trigger that keeps follicles cycling irregularly, meaning the shedding never fully stops even in the absence of a single acute stressor. Management focuses on identifying and addressing every possible contributing factor simultaneously — nutritional deficiencies, thyroid status, iron stores, and sleep quality — rather than treating a single cause.
Frontal Fibrosing Alopecia (FFA)
Frontal fibrosing alopecia is a progressive scarring alopecia characterised by a symmetrical recession of the frontal hairline, often accompanied by loss of eyebrows and eyelashes, and it has risen sharply in incidence among post-menopausal women over the past three decades in a pattern that epidemiologists have not fully explained. Unlike the diffuse thinning of androgenetic alopecia, FFA destroys follicles permanently through a lymphocytic inflammatory process, meaning early identification and treatment matters enormously — lost hair in affected areas does not regrow. Dermatological evaluation is essential, as this type requires anti-inflammatory or immunosuppressive treatments rather than the hormonal or nutritional approaches used for other hair loss types.
Lichen Planopilaris
Lichen planopilaris (LPP) is a related scarring alopecia in which the immune system attacks the hair follicle, causing patchy, irregular hair loss often accompanied by scalp redness, scaling, and itching at the follicle openings — symptoms that distinguish it from non-scarring types. It shares a similar inflammatory mechanism with frontal fibrosing alopecia and may represent a related condition on the same spectrum, though its distribution tends to be more scattered across the crown rather than following a defined hairline pattern. Like FFA, it causes permanent follicle destruction if untreated, and any woman noticing scalp inflammation alongside patchy loss should seek a dermatology referral rather than self-treating.
Alopecia Areata
Alopecia areata is an autoimmune condition in which the immune system targets hair follicles, producing distinct round or oval patches of complete hair loss — a pattern that is visually unlike the diffuse thinning of hormonal hair loss. Immune dysregulation associated with the menopausal transition may act as a trigger or accelerant in women who are already genetically predisposed, and there is observational evidence suggesting flare-ups cluster around periods of significant hormonal change. Treatment is immune-directed rather than hormone-directed, and a new class of JAK inhibitor drugs has shown promising results in clinical trials for moderate-to-severe cases.
Hypothyroid-Related Hair Loss
Thyroid dysfunction — both overt and subclinical hypothyroidism — produces diffuse hair thinning that is clinically indistinguishable from hormonal hair loss without a blood test, and hypothyroidism becomes significantly more prevalent in women during and after the menopausal transition. The mechanism involves thyroid hormone receptors in the hair follicle that regulate the growth cycle; without adequate thyroid hormone, follicles spend proportionally more time in the resting phase. Because symptoms of hypothyroidism — fatigue, weight gain, low mood, brain fog — heavily overlap with menopause symptoms, thyroid function is frequently undertested, and treating the thyroid abnormality rather than the menopause is what resolves the hair loss.
Iron-Deficiency-Related Hair Loss
Iron is essential for DNA synthesis in the rapidly dividing cells of the hair follicle matrix, and even a ferritin level that falls within a laboratory's 'normal' range may be insufficient to support healthy hair growth — most trichologists suggest a ferritin level above 70 µg/L is needed for optimal follicle function, a threshold that standard iron panels rarely flag as a problem. Heavy or irregular perimenopausal periods frequently drive ferritin down precisely at the stage of life when hormonal hair loss also begins, making it genuinely difficult to separate the two causes without testing. Correcting iron stores — through dietary adjustment, supplementation, or addressing the bleeding pattern itself — can produce significant improvement, but results take four to six months to become visible due to the length of the hair growth cycle.
Medication-Induced Hair Loss (Drug-Related Telogen Effluvium)
A range of medications commonly prescribed to menopausal women can independently trigger diffuse hair shedding, including certain antidepressants, beta-blockers, statins, anticoagulants, and some formulations of hormone therapy — progestins with higher androgenic activity are the most frequently implicated HRT-related cause. This matters because a woman who starts HRT hoping to address hormonal hair loss may inadvertently worsen it if the specific progestogen used has significant androgenic activity at the follicle, a distinction that is rarely explained at the point of prescribing. Reviewing the medication list with a clinician and — where appropriate — switching to a lower-androgenicity progestogen (such as micronised progesterone) or adjusting other medications may resolve the shedding without additional treatment.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.